ArticleBritish journal of cancer2015
The significant survival advantage of female sex in nasopharyngeal carcinoma: a propensity-matched analysis.
Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Different outcomes by sex in metastatic gastrointestinal stromal tumor patients receiving imatinib: a trial-level analysis.International journal of clinical oncology · 2025Pooled it
- The burden of nasopharyngeal carcinoma in countries of the Association of Southeast Asian Nations (ASEAN), 1990-2023: findings from the Global Burden of Disease Study 2023.Journal of cancer research and clinical oncology · 2026Article
- Female sex is associated with worse survival in laryngeal head and neck squamous cell carcinoma.The oncologist · 2026Article
- SARS-CoV-2 infection and its effects on toxicity and survival in non-metastatic nasopharyngeal carcinoma: a matched cohort study.BMC cancer · 2026Article
- Androgen receptor may promote tumor progression via TTF-1/EGFR pathway in metastatic nasopharyngeal carcinoma.Translational oncology · 2026Article
- Integration of neutrophil to high-density lipoprotein ratio for prognostic assessment of nasopharyngeal carcinoma: a large-scale long-term retrospective study.Frontiers in physiology · 2026Article
- Reproduction outcomes and prognostic significance of pregnancy after nasopharyngeal carcinoma treatment.Annals of medicine · 2025Article
- PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Examining the Impact of Race and Sex on the Incidence of Positive Surgical Margins in Oral Cavity Squamous Cell Carcinoma.Head & neck · 2025Article
- Prognostic analysis of early-onset and late-onset nasopharyngeal carcinoma: a retrospective study.Discover oncology · 2024Article
- Article
- Gender-Specific Survival of Nasopharyngeal Carcinoma in Endemic and Non-Endemic Areas Based on the US SEER Database and a Chinese Single-Institutional Registry.Clinical epidemiology · 2024Article
- Impact of sex on treatment-related adverse effects and prognosis in nasopharyngeal carcinoma.BMC cancer · 2023Article
- Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling.JMIR public health and surveillance · 2023Article
- Health Insurance Coverage and Survival Outcomes among Nasopharyngeal Carcinoma Patients: A SEER Retrospective Analysis.Journal of neurological surgery. Part B, Skull base · 2023Article
- Nasopharyngeal carcinoma. A "different" head and neck tumour. Part B: treatment, prognostic factors, and outcomes.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2023Review
- Sex and gender perspectives in colorectal cancer.ESMO open · 2023Review
- Prognostic models for early and late tumor progression prediction in nasopharyngeal carcinoma: An analysis of 8292 endemic cases.Cancer medicine · 2023Article
- Development and validation of an MRI-based radiomic model for predicting overall survival in nasopharyngeal carcinoma patients with local residual tumors after intensity-modulated radiotherapy.BMC medical imaging · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhether females have better survival than males in nasopharyngeal carcinoma is barely acknowledged and the exact explanations remain unknown.
methodsOverall, 5929 patients receiving treatment between January 2005 and December 2010 were separately stratified by stage into early and advanced stage groups, and by age into premenopausal (⩽45 years), menopausal (46-54 years) and postmenopausal (⩾55 years) groups. Matched males and females in each group were identified using the propensity score matching method. Differences in disease-free survival (DSS), overall survival (OS), distant metastasis-free survival (DMFS) and locoregional relapse-free survival (LRFS) were estimated by the Kaplan-Meier method and Cox regression model.
resultsOverall, 398, 923, 744, 319 and 313 pairs of males and females were matched in early stage, advanced stage, premenopausal, menopausal and postmenopausal group, respectively. Females showed significant advantage over males across all end points in both early and advanced stage groups (P⩽0.042). However, this advantage persisted at premenopausal age (P⩽0.042), declined during menopause (DMFS, P=0.021; DSS, P=0.100; OS, P=0.693; LRFS, P=0.330) and totally disappeared at postmenopausal age (P⩾0.344).
conclusionsSex significantly affects NPC survival, with a definite female advantage regardless of tumour stage. Intrinsic biologic traits appear to be the exact explanation according to the declining magnitude of sex effect with age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.